



Working together to outsmart **HUNTINGTON'S DISEASE**

Learn about a clinical research study investigating cognitive skills in those with early Huntington's disease – and help advance the potential future of HD.

OutsmartHD.com




About the SURVEYOR Study

The SURVEYOR Study is evaluating the safety and effect of an investigational oral drug in adults with early Huntington's disease (HD). This drug is being tested to see if it can specifically target cognitive symptoms and your ability to perform everyday tasks. Investigational drugs are not approved by a health authority for any use, as the safety and efficacy have not been established.

The study lasts up to 10 weeks and includes 6 visits to the study office. You may invite a study partner to attend study visits and help you complete study activities. People without HD will also be enrolled in the study, so your study partner may also be able to be a participant.

There will be an open-label extension (OLE) study, which is planned to begin later in 2022. Participants who are interested can speak to the study team.



Study eligibility is determined during the Screening period. On these visits, you will:

1. Meet with the study doctor and staff
2. Review additional eligibility criteria
3. Have an initial evaluation and assessments
4. Complete study questionnaires

How Do I Qualify?

To be eligible for the study you must:

- Be 25 to 65 years of age
- Have been diagnosed with early Huntington's disease
- Hold a current driver's license, have 5+ years of driving experience, and currently drive more than once per week*
- Be ambulatory (able to walk)

*This study will include an optional driving simulator to evaluate cognitive skills while performing an everyday task.

The study doctor will discuss additional eligibility requirements.



If you qualify and decide to participate:

- A study doctor will closely monitor you, your symptoms, and your overall health
- All study-related procedures and the investigational oral drug will be provided at no cost
- Transportation assistance may be available, if needed

Your safety is the highest priority while participating. If you have questions or concerns at any point throughout the study, a study staff member is available. The study staff can also tell you about their specific COVID-19 safety protocols.

Your participation in the SURVEYOR Study is completely voluntary. If you decide to participate in this research study, you are free to withdraw at any time, for any reason, without any penalty or effect on your medical care.



About Huntington's Disease

Huntington's disease is a progressive brain condition that is passed down in families.^{1,2} It causes uncontrolled movement, decline of mental (cognitive) abilities, and emotional issues.²

- Huntington's disease is caused by a genetic mutation^{1,2}
- Symptoms typically appear between the ages of 30 and 50, but can occur earlier or later^{1,3}
- If a parent has Huntington's disease, there is a 50/50 chance that their child will inherit it¹

Cognitive symptoms may include:^{1,4}

- Difficulty paying attention
- Trouble thinking through steps of an activity
- Difficulty thinking through complex problems
- Difficulty planning, remembering, and staying on task
- Impaired judgment
- Difficulty with multitasking

As Huntington's disease progresses, it will become more and more difficult to continue performing daily activities. Although there is no cure for Huntington's disease, there are ways to help manage some of the physical and emotional symptoms.¹ Currently no treatments are approved to specifically manage cognitive symptoms. Talk to your doctor if you have any questions about Huntington's disease or its symptoms.



Learn More About the SURVEYOR Study:

visit

OutsmartHD.com



References:

1. Overview of Huntington's Disease. Huntington's Disease Society of America. Accessed March 03, 2022. <https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/>
2. Huntington disease. Medline Plus/US National Library of Medicine. Updated November 03, 2021. Accessed March 03, 2022. <https://medlineplus.gov/genetics/condition/huntington-disease/>
3. Overview – Huntington's disease. National Health Service (United Kingdom). Updated March 29, 2021. Accessed March 03, 2022. <https://www.nhs.uk/conditions/huntingtons-disease/>
4. What is HD? Cognitive Symptoms. Huntington's Disease Society of America. Accessed March 03, 2022. <https://hdsa.org/what-is-hd/cognitive-symptoms/>

© 2022 Sage Therapeutics, Inc. All Rights Reserved. SAGE THERAPEUTICS and the SAGE THERAPEUTICS logo are registered trademarks of Sage Therapeutics, Inc. SURVEYOR STUDY, and the SURVEYOR STUDY logo are trademarks of Sage Therapeutics, Inc.

Patient Brochure_Surveyor_V1_03MAR2022

MRC-718-00209 MARCH 2022